Clinical genitourinary cancer · 2025
Increased Severity of Prostate Cancer Presentation in an Appalachian Cohort Compared to National Data.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Simpkins Marvin A, Douglas Garrett, Yablonsky Emily, Wyner Lawrence, Blankenship Justyn
Аннотация
BACKGROUND: Prostate cancer is the second leading cause of cancer death among American men, with known disparities by geography, socioeconomic status, and access to care. Data on prostate cancer presentation in Appalachia are scarce.
METHODS: We retrospectively reviewed 160 first-time transrectal ultrasound-guided prostate biopsies from 2022 to 2024 at a single Appalachian institution and compared them to 8776 positive biopsies from the PLCO trial. Gleason scores were grouped as 1 (≤ 6), 2/3 (7), 4 (8), and 5 (≥ 9). We used chi-square tests to compare grade distributions and PSA categories (< 4, 4-10, 10-20, > 20 ng/mL), Wilcoxon rank-sum tests for age and median PSA by grade, and sequential logistic regression (unadjusted; +age; +PSA+age) to identify independent predictors of Appalachian cohort membership.
RESULTS: Appalachian patients were more likely to present with Grade 4 (19.1% vs. 7.9%) and Grade 5 disease (10.1% vs. 5.0%; χ² = 49.2, P < .001) and had older median age (e.g., Grade 1: 66 vs. 63 years, P = .0033) and higher median PSA (e.g., Grade 1: 8.6 vs. 5.7 ng/mL, P = .0001). PSA category distribution also differed (χ² = 44.8, P < .001). In fully adjusted models, Grade 4 (OR 2.54, P = .002) and Grade 5 (OR 2.80, P = .002) remained independent predictors of Appalachian cohort membership, while PSA was not (P = .280).
CONCLUSIONS: Appalachian patients exhibit a disproportionately high prevalence of advanced-grade prostate cancer that persists after accounting for age and PSA. Tailored, region-specific strategies are needed to enhance early detection and reduce persistent disparities in care.
METHODS: We retrospectively reviewed 160 first-time transrectal ultrasound-guided prostate biopsies from 2022 to 2024 at a single Appalachian institution and compared them to 8776 positive biopsies from the PLCO trial. Gleason scores were grouped as 1 (≤ 6), 2/3 (7), 4 (8), and 5 (≥ 9). We used chi-square tests to compare grade distributions and PSA categories (< 4, 4-10, 10-20, > 20 ng/mL), Wilcoxon rank-sum tests for age and median PSA by grade, and sequential logistic regression (unadjusted; +age; +PSA+age) to identify independent predictors of Appalachian cohort membership.
RESULTS: Appalachian patients were more likely to present with Grade 4 (19.1% vs. 7.9%) and Grade 5 disease (10.1% vs. 5.0%; χ² = 49.2, P < .001) and had older median age (e.g., Grade 1: 66 vs. 63 years, P = .0033) and higher median PSA (e.g., Grade 1: 8.6 vs. 5.7 ng/mL, P = .0001). PSA category distribution also differed (χ² = 44.8, P < .001). In fully adjusted models, Grade 4 (OR 2.54, P = .002) and Grade 5 (OR 2.80, P = .002) remained independent predictors of Appalachian cohort membership, while PSA was not (P = .280).
CONCLUSIONS: Appalachian patients exhibit a disproportionately high prevalence of advanced-grade prostate cancer that persists after accounting for age and PSA. Tailored, region-specific strategies are needed to enhance early detection and reduce persistent disparities in care.